press release archive

Rigel Pharmaceuticals to Present at 2003 Credit Suisse First Boston Healthcare Conference

South San Fransisco, CA - October 31, 2003

Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that James M. Gower, Rigel's Chairman and Chief Executive Officer, is scheduled to present at the 2003 Credit Suisse First Boston Healthcare Conference at 4:00 p.m. Mountain Time, November 13, 2003 at the Arizona Biltmore in Phoenix, Arizona.

For those who are unable to attend the conference, there will be a live audio webcast of Gower's presentation which can be accessed by going to www.rigel.com and clicking on the link from the homepage. A replay will be available at the same site for 30 days.

About Rigel (www.rigel.com)
Rigel's mission is to become a source of novel, small-molecule drugs to meet large, unmet medical needs. Rigel has identified three lead product development programs: mast cell inhibition to treat immunologic diseases such as asthma/allergy and autoimmune disorders, antiviral agents to treat hepatitis C, and ligases, a new class of cancer drug targets. Rigel has begun clinical testing of its first product candidate, R112, for allergic rhinitis, and plans to begin clinical trials of three additional drug candidates for the treatment of hepatitis C, rheumatoid arthritis and asthma, by the end of 2004.

Rigel Contact: Raul Rodriguez (1-650-624-1302)